Originally published in Fierce Biotech. EnteroBiotix has rounded up $21.5 million in a series A financing to advance a pipeline of drugs targeting the microbiome, which is believed to play a role in overall health.

Originally published in Endpoint News. Scottish biopharma Enterobiotix today announced the closing of its $21.5 million Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and support its product development and manufacturing capabilities.

Glasgow, Scotland – 7th September 2021 – EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities.